Cancer Medicine

Scope & Guideline

Unveiling the future of cancer therapies and treatments.

Introduction

Welcome to your portal for understanding Cancer Medicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2045-7634
PublisherWILEY
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2012 to 2024
AbbreviationCANCER MED-US / Cancer Med.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Cancer Medicine' aims to foster the understanding and treatment of cancer through innovative research and clinical findings. It serves as a platform for disseminating vital insights into the biology of cancer, treatment methodologies, and patient care, emphasizing a multidisciplinary approach to cancer management.
  1. Clinical Trials and Therapeutics:
    The journal publishes research on the efficacy and safety of novel cancer therapies, including clinical trials of new drug combinations, immunotherapies, and targeted therapies.
  2. Cancer Biology and Genetics:
    Research focusing on the underlying genetic and molecular mechanisms of cancer progression and resistance, including studies on mutations, epigenetics, and tumor microenvironments.
  3. Patient-Centered Care and Quality of Life:
    Emphasis on patient-reported outcomes, psychosocial aspects of cancer care, and interventions to improve patients' quality of life during and after treatment.
  4. Epidemiology and Public Health:
    Studies assessing cancer incidence, risk factors, and disparities in cancer care, aiming to inform public health strategies and screening recommendations.
  5. Innovative Diagnostic Techniques:
    Research on novel diagnostic approaches, including imaging techniques, biomarker discovery, and liquid biopsies, to enhance cancer detection and monitoring.
  6. Integrative and Multidisciplinary Approaches:
    Focus on collaborative strategies involving various specialties to improve patient outcomes in cancer treatment and survivorship.
The journal has identified several emerging themes that reflect the latest advancements and interests in cancer research. These trends indicate a growing focus on innovative approaches and patient-centered care strategies.
  1. Immunotherapy and Combination Therapies:
    A significant increase in research on immunotherapy, particularly combination therapies that integrate immune checkpoint inhibitors with other treatment modalities, is evident.
  2. Personalized and Precision Medicine:
    There is a growing emphasis on research that tailors treatment based on individual genetic and molecular profiles, leading to more effective patient-specific interventions.
  3. Artificial Intelligence and Machine Learning Applications:
    The incorporation of AI and machine learning in cancer diagnostics, treatment prediction, and patient management is becoming a central focus in recent publications.
  4. Microbiome and Cancer Interactions:
    Emerging research exploring the role of the gut microbiome in influencing cancer outcomes and treatment responses is gaining traction.
  5. Health Disparities and Equity in Cancer Care:
    Increased attention to understanding and addressing disparities in cancer incidence, treatment access, and outcomes among different demographic groups is reflected in recent studies.
  6. Psycho-Oncology and Mental Health:
    There is a notable rise in research addressing the psychological impacts of cancer, including patient mental health, coping strategies, and supportive care interventions.

Declining or Waning

While 'Cancer Medicine' continues to expand its scope in various areas, some themes have shown a decline in publication frequency or emphasis, reflecting shifts in research priorities and emerging trends in cancer care.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable reduction in studies exclusively focusing on traditional chemotherapy regimens, as the field shifts toward personalized and targeted therapies.
  2. Single-Agent Trials:
    Research centered around single-agent therapies is waning in favor of combination therapies that leverage synergistic effects to improve outcomes.
  3. Basic Science Research:
    While foundational studies remain important, there has been a shift towards more translational research that directly informs clinical practice and patient care.
  4. Local Treatment Modalities:
    Publications focusing solely on local treatment methods, such as surgery or radiotherapy without integrative approaches, are becoming less frequent as multidisciplinary strategies gain traction.
  5. Longitudinal Studies of Survivorship:
    The focus on long-term survivorship studies has decreased, possibly due to the increasing emphasis on immediate therapeutic outcomes and quality of life during treatment.

Similar Journals

ANTICANCER RESEARCH

Exploring Breakthroughs in Oncology and Medicine
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

JNCI-Journal of the National Cancer Institute

Transforming cancer treatment with trusted knowledge.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

World Journal of Gastrointestinal Oncology

Fostering innovation in the fight against gastrointestinal disorders and cancer.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

BREAST CANCER RESEARCH AND TREATMENT

Innovating Research, Transforming Treatment
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

CANCER INVESTIGATION

Transforming knowledge into breakthroughs in cancer care.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

ONCOLOGY RESEARCH

Elevating Knowledge in the Fight Against Cancer
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Current Urology

Exploring the Frontiers of Urology and Reproductive Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Oncology Letters

Connecting Researchers to Revolutionize Cancer Care
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Journal of Cancer

Unlocking the complexities of cancer together.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

BULLETIN DU CANCER

Illuminating the path to effective cancer therapies.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.